Posted on August 2, 2014, in cardiology, shared decision making and tagged Adnan Chhatriwalla, angina, bare metal stents, decision aids, drug-eluting stents, health care costs, heart disease, percutaneous coronary intervention, shared decision making. Bookmark the permalink. 1 Comment.
StatCounter
Follow me on Twitter
My Tweets-
Recent posts
- Funding for C3FIT Trial Approved by PCORI
- Talk at QCOR 2018
- Talk at CVCT 2017
- Salim Yusuf on nutrition and cardiovascular disease
- LDL-Lowering Genetic Variants Linked to Increased Risk of Diabetes
- Diminishing returns in medical therapy
- More data on alirocumab and diabetes risk
- Patient peer review
- 2013 Gina Kolata article on PKSK9 inhibitors was inaccurate
- Do PCSK9 inhibitors affect diabetes risk?
- Thoughts on the recent PCSK9 inhibitor studies
- Advertising LVADs
- IMPROVE-IT trial
- National Physicians Alliance conference
- American Heart Association journal announces new Patient Viewpoints
- Input needed on stent decision aid
- Making health care more patient-centered
- My new Walking Gallery jacket
- Assessment 2020 blog
- New series of articles in Circulation: Cardiovascular Quality and Outcomes
Archives
- Join 3,915 other subscribers
Search
-
-
Danielle OwenHello mate greeat blog
- More data on alirocumab and diabetes risk | Marilyn Mann's Blog[…] I happened to see an abstract from the American Heart Association Scientific Sessions in w
-
marilynmannMy friend Laura Newman was having trouble commenting so she emailed me this comment: "Excellent post
- Cardiology Drugs Of The Year: New, Old, And Not-So-Funny | VantageWire[…] Old Drug Of The Year LCZ696 represents the future of cardiology. Ezetimibe, by contrast, r
-
marilynmannAlso, please check out this post on the Medical Professionalism Blog: http://blog.abimfoundation.org
-
marilynmannThere are a number of comments on the two versions of the decision aid over on the e-patients.net bl
-
marilynmannDear Robert I'm certainly glad to hear you are in good health. I agree with you that data are lackin
-
Robert BramelHi Marilyn! I was just doing another one of my searches on FH and encountered your blog. The post mu
- Assessment 2020 blog (79)
- Heart and Stroke Foundation “make death wait” campaign: effective advocacy or unnecessary scare tactics? (10)
- Abbott Laboratories sponsors review article on its own drug (8)
- More on the need for data sharing — the Tamiflu example (7)
- Hayward and Krumholz: Open Letter to the Adult Treatment Panel IV of the National Institutes of Health (7)
- Data sharing as a moral imperative (5)
- Sunday links (5)
- FDA warns Chantix may increase risk of cardiovascular events (4)
- Profile on Harlan Krumholz (3)
- Why the new indication for Vytorin and Zetia should not be approved (3)
- September 2018 (1)
- April 2018 (1)
- December 2017 (1)
- February 2017 (1)
- October 2016 (1)
- June 2016 (1)
- December 2015 (1)
- June 2015 (2)
- May 2015 (1)
- March 2015 (1)
- January 2015 (1)
- December 2014 (1)
- November 2014 (1)
- August 2014 (2)
- April 2014 (2)
- March 2014 (1)
- February 2014 (1)
- December 2013 (1)
- September 2013 (1)
- October 2012 (4)
- September 2012 (1)
- August 2012 (1)
- July 2012 (1)
- June 2012 (1)
- May 2012 (4)
- April 2012 (5)
- March 2012 (2)
- February 2012 (2)
- January 2012 (2)
- December 2011 (1)
- November 2011 (2)
- September 2011 (3)
- August 2011 (1)
- July 2011 (4)
- June 2011 (3)
- May 2011 (1)
- February 2011 (1)
- November 2010 (1)
- October 2010 (3)
- May 2010 (1)
alirocumab American Heart Association Avandia blood glucose cardiology cardiovascular risk cholesterol Circulation: Cardiovascular Quality and Outcomes conflicts of interest Consumer Reports data sharing Dean Follmann diabetes drug safety EBM Ellis Unger evolocumab ezetimibe familial hypercholesterolemia Harlan Krumholz health care costs heart attacks heart disease hypertension Joseph Ross Merck Meridia Milton Packer open science PCSK9 inhibitors Peter Doshi publication bias Rodney Hayward rofecoxib Sanjay Kaul shared decision making SHARP trial statins Steve Nissen stroke Tamiflu Tom Jefferson Vioxx Vytorin Zetia- cardiology (37)
- plant sterols (3)
- conflicts of interest (2)
- data sharing (6)
- drug safety (14)
- health care (10)
- health care costs (3)
- medical device safety (2)
- nutrition (1)
- politics (1)
- scholarly journals (6)
- shared decision making (3)
- Uncategorized (10)
-
Blogroll
- 1 Boring Old Man
- A Dose of History
- A New Merck: Reviewed
- Adam G. Dunn
- American Heart Association blog
- An Ounce of Evidence — Health Policy
- Ase Fixes Science
- Avian Flu Diary
- Bad Science
- Ben Goldacre — secondary blog
- Blogging Stroke
- CardioBrief
- Casey Quinlan
- Cobalt-60: Musings on medical ethics, and end-of-life care by Dr. Jay Detsky
- Common Sense Family Doctor
- Doctor David's Blog
- e-Patient Dave
- e-patients.net
- Evidence in Medicine
- Evidence Live Blog
- Evidently Cochrane
- Fear and Loathing in Bioethics
- Genomics, Medicine, and Pseudoscience
- Glyn Elwyn Blog
- Harlan Krumholz Outcomes blog
- Health Care Basics
- Health Care Renewal
- Health News Watchdog blog
- Health: An Interdisciplinary Blog
- HealthLawProf Blog
- Healthy buzz
- Hooked: Ethics, Medicine, and Pharma
- IP Policy Committee blog
- JAMA Internal Medicine Blog
- Kentucky Health Policy Institute blog
- KER Unit Blog (Mayo Clinic)
- KevinMD
- Laika's MedLibLog
- Less is More Medicine
- MacArthur Lab Blog
- Managing Healthcare Costs
- mathbabe
- MaxSpeak
- Medicine and Social Justice
- milescorak: Economics for public policy
- Minimally Disruptive Medicine
- Miss Treated: Fighting Misogyny in the Medical Profession One Story at a Time
- Neurologica Blog
- Neuroskeptic
- Not Running a Hospital
- Now@NEJM
- nutsci.org Nutritional Science!
- Occupy Healthcare
- Open Medicine EU
- Open Science
- OpenHeart
- Patient POV
- Pharmacritique
- Pharmagossip
- Pharmalot
- Postscript
- Regina Holliday's Medical Advocacy Blog
- Respectful Insolence
- Rethink Aid
- Richard Lehman's Journal Review
- Robert M. Califf, MD
- Science-Based Medicine
- Science-Based Pharmacy
- Somewhere North of 140 Characters
- Speaking of Medicine
- Statistically funny
- Talking to your doctor: a patient's guide to communication in the exam room and beyond
- Ted Eytan, M.D.
- Tessa Richards
- The Beating Edge
- The Carlat Psychiatry Blog
- The File Drawer
- The Incidental Economist
- The Lab @ Edmond J. Safra Center for Ethics – Blog
- The Medicine Show
- Thom Walsh Blog
- To Conquer Confusion
- University Diaries
- Voices for Safer Care
- Wachter's World
- Weighty Matters
- White Coat Underground
- Whole Health Source
Family
Links
There are a number of comments on the two versions of the decision aid over on the e-patients.net blog. Here are my comments:
Comments that apply to both versions:
1. “Repeat heart procedure” is not self-explanatory. Most patients do not understand what a cardiologist means by a “procedure” or “surgery,” or what the difference is between those terms. Would the consequence of stent blockage always be insertion of another stent? If so, perhaps “repeat stent procedure” would work.
2. You need to indicate that the numbers are out of 100 people. Also suggest putting percentages in parentheses.
3. The meaning of green and red in the figure is not explained. Suggest that the relevant numbers be shown in red or green, as applicable.
4. Suggest a more explanatory label on the Y axis (e.g., “Number of people per 100 who will (red) or will not (green) need a repeat stent procedure”).
5. I wonder if there is anything beyond one year that the patient should know?
6. With respect to bleeding, how often would this result in hospitalization and serious complications?
7. Agree with the commenters who stated that it is not clear what would happen in the case of an emergency requiring surgery.
Comments on Option 1
1. You need to state the time period (i.e., one year).
2. Suggest deleting all the check marks and inserting “Yes” in the boxes for stopping the medicine early.
3. The meaning of “blood thinner medicine” is not clear. The patient needs to know that they will need to take aspirin for the rest of their life plus an extra blood thinner such a Plavix for the required period.
Comments on option 2
1. The meaning of “extra blood thinner” will not be clear to most people. You need to state that aspirin will be required indefinitely in both cases, plus an extra blood thinner such as Plavix for the required period.
General impression: I found Option 2 much easier to read and digest.
I am not sure the figure works that well. To me, the important thing to know would be the percentage of people who need repeat procedures. I suggest testing a version of the figure that only shows that information. You could still have the number of people who don’t need a repeat procedure explained in the text.
LikeLike